About the center
The Center for Embryonic Cell and Gene Therapy at Oregon Health & Science University, led by Shoukhrat Mitalipov, Ph.D., is pioneer of the technique to produce rejection-proof, genetically matched embryonic human stem cells from skin cells using somatic cell nuclear transfer (SCNT). Our program connects basic cell science, translational research and clinical testing in a virtuous cycle of discovery and innovation. Research performed at the center will keep people healthier as they age, restore mobility for patients with Parkinson's disease or spinal injuries, and stop familial diseases before they affect a new generation.
A groundbreaking discovery
In May 2013, Dr. Mitalipov and his team published a study in Cell that describes a new process for creating human stem cells from skin cells. Stem cells are thought to hold promise for treating various degenerative diseases, but finding a source of embryonic stem cells—which can be reprogrammed into any other cell type—has been an obstacle to progress in developing such treatments. The process described by Dr. Mitalipov, referred to as SCNT, removes chromosomes from a human donor's unfertilized egg and then replaces them with new DNA from a patient's skin cells. This discovery sparked more than 2,000 news reports internationally and was named a top 10 scientific breakthrough of 2013.
SCNT provides an alternative to stem cells derived from fertilized human embryos. It may also provide advantages over the induced pluripotent stem cell (iPSC) method, which involves genetic programming changes in mature skin cells to transform them to an embryonic-like state.
Breaking the cycle of disease
Another facet of Dr. Mitalipov's work could, for the first time in history, break the cycle of diseases passed from mother to baby through mutations in mitochondrial DNA. Such mutations impact one out of every 4,000 babies born, causing a wide variety of diseases including autism, blindness, muscular dystrophy, cardiovascular disease, and seizures.
Dr. Mitalipov's mastery of cell manipulation is at the heart of a promising therapy that could prevent inherited mitochondrial diseases. The method, first proven in non-human primate models in 2009, was demonstrated successfully in human cells in 2012. It involves replacing a mother's mutated mitochondrial DNA with the equivalent material from a healthy egg, effectively retaining 99 percent of the mother's DNA but with healthy mitochondrial DNA. Upon FDA approval, this technique is ready for human clinical testing.
In the News
Dr. Mitalipov's stem cell discovery, published in Cell last May, was named Top 10 scientific breakthrough of 2013 by several international publications including Nature, Science, Time, Discover, National Geographic, and The Week.
ContactMedia inquiries: OHSU Strategic Communications
General inquiries: firstname.lastname@example.org
About our Lab Research
Our team of research associates, postdoctoral fellows, MD/PhD students and research assistants is interested in studying some of the fundamental questions in early embryo development and stem cell biology. We use state-of-the-art technologies in molecular biology, biochemistry, cell biology, and embryology to understand genetic and epigenetic mechanisms governing the developmental program. The basic research conducted in the lab provides new insights into biology of totipotent and pluripotent cells and reprogramming of aged somatic cells to the totipotency and pluripotency by somatic cell nuclear transfer (SCNT) and iPS approaches. Particularly, we are interested in the role of mitochondria and mitochondrial genome during development and aging and in reprogramming and re-setting the developmental program in experimentally created totipotent and pluripotent cells derived from aged somatic cells.